linezolid + ceftazidime

Linezolid + ceftazidime is a combination of two antibiotics used for their complementary antibacterial spectra. Linezolid is a synthetic oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S ribosomal subunit, thereby preventing formation of the functional 70S initiation complex essential for bacterial reproduction. It is primarily effective against Gram-positive bacteria, including resistant strains such as MRSA and VRE[2][6][8]. Ceftazidime is a third-generation cephalosporin beta-lactam antibiotic that exerts its bactericidal effect by inhibiting penicillin-binding proteins (PBPs), disrupting cell wall synthesis in susceptible bacteria, with strong activity against Gram-negative organisms[3]. The combination may be considered in clinical scenarios where both Gram-positive and Gram-negative coverage are required; however, studies indicate no significant synergistic or antagonistic interaction between these agents when used together[1][4]. This combination has been explored in fixed-dose formulations for broad-spectrum antibacterial therapy[4].